Remibrutinib clinical trials
Also written LOU064.
ClinicalTrials.gov finds 41 studies for remibrutinib. How that becomes 35 here
Every study that search finds has been read, to see whether and how it gives remibrutinib. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 41Found by its intervention search · See all 41 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 33 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- +1Give it under a name that search misses: a biosimilar’s code or a misspelling
- 42Give remibrutinib to participants
- −7Observe patients on it, or give it outside a trial
- 35Test it: the count on this site
Get an email when these change. Save the remibrutinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 30 Sept 2025 · RHAPSIDO · NDA 218436 (FDA, Drugs@FDA)
- European Union
- 23 Apr 2026 · Rhapsido · EMEA/H/C/006313 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
34 studies that test it; most in 2025 (8); 1 more planned to start later
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2019 | 5 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 4 |
| 2025 | 8 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 34 · Other 1
Novartis Pharmaceuticals (34) · Moein Amin (1)
Often tested with
Tested in the same studies.
Iscalimab (1) · LYS-006 (1) · Arumakimig (1) · Ianalumab (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 6, 4 in phase 3
Studies that test remibrutinib, phase 3 first.
- Nov 202624 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-upPhase 3 · Novartis Pharmaceuticals
- Feb 2027A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistaminesPhase 3 · Novartis Pharmaceuticals
- May 2027A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)Phase 3 · Novartis Pharmaceuticals
- Jun 2027A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis SuppurativaPhase 3 · Novartis Pharmaceuticals
- Aug 2027Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic UrticariaPhase 2 · Novartis Pharmaceuticals
- Nov 2027A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HSPhase 1 · Novartis Pharmaceuticals
Studies
Open first, then newest update. How each study uses remibrutinib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 35
- A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)RecruitingPhase 2Novartis PharmaceuticalsNCT07681271In papulopustular rosaceaWritten as LOU064Report a problem
- A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HSRecruitingPhase 1Novartis PharmaceuticalsNCT07855276Tissue effects in hidradenitis suppurativaWritten as LOU064Report a problem
- A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)RecruitingPhase 3Novartis PharmaceuticalsNCT07700056In chronic pruritus of unknown originWritten as RemibrutinibReport a problem
- An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSRecruitingPhase 3Novartis PharmaceuticalsNCT07665437Extension in hidradenitis suppurativaWritten as RemibrutinibReport a problem
- Remibrutinib Open Label Roll-over Post-trial Access ProtocolRecruitingPhase 3Novartis PharmaceuticalsNCT07456891Roll-over post-trial accessWritten as RemibrutinibReport a problem
- A 52-week Study of Remibrutinib in IgE-mediated Food AllergyRecruitingPhase 3Novartis PharmaceuticalsNCT07768371In IgE-mediated food allergyWritten as RemibrutinibReport a problem
- A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)RecruitingPhase 3Novartis PharmaceuticalsNCT07811869In chronic pruritus of unknown originWritten as RemibrutinibReport a problem
- Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 WeeksRecruitingPhase 3Novartis PharmaceuticalsNCT07816328A remibrutinib-based treatment algorithm in urticariaWritten as RemibrutinibReport a problem
- Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.RecruitingPhase 3Novartis PharmaceuticalsNCT06846281After switching from ocrelizumab in relapsing multiple sclerosisWritten as Remibrutinib oral treatmentReport a problem
- A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisRecruitingPhase 3Novartis PharmaceuticalsNCT07225504In secondary progressive multiple sclerosisWritten as Remibrutinib (blinded)Report a problem
- Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic UrticariaRecruitingPhase 2Novartis PharmaceuticalsNCT06865651How it works in chronic urticariaWritten as RemibrutinibReport a problem
- A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MSNot yet recruitingPhase 2Moein AminNCT07222956By MR imaging in multiple sclerosisWritten as Remibrutinib (Open Label)Report a problem
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05156281Against teriflunomide in relapsing multiple sclerosis (REMODEL-2)Written as RemibrutinibReport a problem
- A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistaminesActive, not recruitingPhase 3Novartis PharmaceuticalsNCT06868212Against dupilumab at early timepoints in urticariaWritten as RemibrutinibReport a problem
- A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy ParticipantsCompletedPhase 1Novartis PharmaceuticalsNCT05753592In liver impairment compared with healthy peopleWritten as Part 1; LOU064 (Remibrutinib)Report a problem
- A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.CompletedPhase 1Novartis PharmaceuticalsNCT07032272In severe renal impairmentWritten as remibrutinibReport a problem
- Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis SuppurativaCompletedPhase 2Novartis PharmaceuticalsNCT03827798One cohort in hidradenitis suppurativa among several investigational drugsWritten as LOU064 25mgReport a problem
- A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistaminesActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05976243In chronic inducible urticariaWritten as RemibrutinibReport a problem
- A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT06799000In hidradenitis suppurativaWritten as Remibrutinib Dose AReport a problem
- 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-upActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05677451In adolescents with chronic spontaneous urticariaWritten as LOU064 (blinded)Report a problem
See all 35 studies that test remibrutinib →
Behind its US label · 2 — the studies the FDA label of RHAPSIDO describes
From the Clinical Studies section of RHAPSIDO (2026-03), as openFDA has it. A study the site does not hold is left out.
- A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 AntihistaminesCompletedPhase 3Novartis PharmaceuticalsNCT05030311Report a problem
- A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistaminesCompletedPhase 3Novartis PharmaceuticalsNCT05032157Report a problem
Tested on its own · 34 — no other medicine in its arm
- A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)RecruitingPhase 2Novartis PharmaceuticalsNCT07681271In papulopustular rosaceaWritten as LOU064Report a problem
- A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HSRecruitingPhase 1Novartis PharmaceuticalsNCT07855276Tissue effects in hidradenitis suppurativaWritten as LOU064Report a problem
- A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)RecruitingPhase 3Novartis PharmaceuticalsNCT07700056In chronic pruritus of unknown originWritten as RemibrutinibReport a problem
- An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSRecruitingPhase 3Novartis PharmaceuticalsNCT07665437Extension in hidradenitis suppurativaWritten as RemibrutinibReport a problem
- Remibrutinib Open Label Roll-over Post-trial Access ProtocolRecruitingPhase 3Novartis PharmaceuticalsNCT07456891Roll-over post-trial accessWritten as RemibrutinibReport a problem
- A 52-week Study of Remibrutinib in IgE-mediated Food AllergyRecruitingPhase 3Novartis PharmaceuticalsNCT07768371In IgE-mediated food allergyWritten as RemibrutinibReport a problem
- A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)RecruitingPhase 3Novartis PharmaceuticalsNCT07811869In chronic pruritus of unknown originWritten as RemibrutinibReport a problem
- Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 WeeksRecruitingPhase 3Novartis PharmaceuticalsNCT07816328A remibrutinib-based treatment algorithm in urticariaWritten as RemibrutinibReport a problem
- Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.RecruitingPhase 3Novartis PharmaceuticalsNCT06846281After switching from ocrelizumab in relapsing multiple sclerosisWritten as Remibrutinib oral treatmentReport a problem
- A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisRecruitingPhase 3Novartis PharmaceuticalsNCT07225504In secondary progressive multiple sclerosisWritten as Remibrutinib (blinded)Report a problem
- Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic UrticariaRecruitingPhase 2Novartis PharmaceuticalsNCT06865651How it works in chronic urticariaWritten as RemibrutinibReport a problem
- A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MSNot yet recruitingPhase 2Moein AminNCT07222956By MR imaging in multiple sclerosisWritten as Remibrutinib (Open Label)Report a problem
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05156281Against teriflunomide in relapsing multiple sclerosis (REMODEL-2)Written as RemibrutinibReport a problem
- A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistaminesActive, not recruitingPhase 3Novartis PharmaceuticalsNCT06868212Against dupilumab at early timepoints in urticariaWritten as RemibrutinibReport a problem
- A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy ParticipantsCompletedPhase 1Novartis PharmaceuticalsNCT05753592In liver impairment compared with healthy peopleWritten as Part 1; LOU064 (Remibrutinib)Report a problem
- A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.CompletedPhase 1Novartis PharmaceuticalsNCT07032272In severe renal impairmentWritten as remibrutinibReport a problem
- A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistaminesActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05976243In chronic inducible urticariaWritten as RemibrutinibReport a problem
- A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT06799000In hidradenitis suppurativaWritten as Remibrutinib Dose AReport a problem
- 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-upActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05677451In adolescents with chronic spontaneous urticariaWritten as LOU064 (blinded)Report a problem
- A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingPhase 3Novartis PharmaceuticalsNCT06840392In hidradenitis suppurativaWritten as Remibrutinib Dose AReport a problem
Showing 20 of 34. See all 34 →
Tested in a combination · 1 — another drug in the study is under test too
Observed · 7 — patients on it are followed, or it is given outside a trial
- Remibrutinib in Real-world Clinical Practice - a South Korea Sub-StudyNot yet recruitingNovartis PharmaceuticalsNCT07920315Real-world use in chronic spontaneous urticaria in South KoreaReport a problem
- Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.RecruitingWashington University School of MedicineNCT07758270Brain imaging during treatment in multiple sclerosis, observedWritten as RemibrutinibReport a problem
- Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)RecruitingNovartis PharmaceuticalsNCT07642557Real-world use in Germany (REASSERT), observedReport a problem
- A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria PatientsRecruitingNovartis PharmaceuticalsNCT07408219Real-world use in chronic spontaneous urticariaReport a problem
- Remibrutinib in Real-world Clinical PracticeRecruitingNovartis PharmaceuticalsNCT07358364Real-world use, observedReport a problem
- Remibrutinib in Real-world Clinical Practice - a US Sub-studyRecruitingNovartis PharmaceuticalsNCT07358780Real-world use in the US, observedReport a problem
- Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous UrticariaAvailableNovartis PharmaceuticalsNCT05170724Managed access programme, outside a trialWritten as RemibrutinibReport a problem
Codes
What other systems call remibrutinib · ClinicalTrials.gg INT001907
- MeSH (NLM) C000722911remibrutinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) I7MVZ8HDNUREMIBRUTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q123499462remibrutinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C175851RemibrutinibOne source FDA
- DrugBank DB16852One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722911 | remibrutinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | I7MVZ8HDNU | REMIBRUTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123499462 | remibrutinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C175851 | Remibrutinib | One source FDA |
| DrugBank | DB16852 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.